CD40 Ligand: Adjuvant for Enhanced Immune Response to Respiratory Syncytial Virus


CDC researchers have developed methods and adjuvants for enhancing a subject's immune response to respiratory syncytial virus (RSV) by inclusion of a CD40 binding protein. RSV has long been recognized as a major respiratory tract pathogen of infants, as well as older children and the elderly. Established, successful methods for preventing RSV are currently unavailable. CD40 ligand (CD40L, also known as CD154) is an important costimulatory molecule found on the T-cell and is critical for the development of immunity. CD40L may provide a novel adjuvant to enhance cytokine and antibody response to RSV, directing a subject's immune response further towards Th1-mediated outcomes rather than a less effective Th2-type response. This Th2-type response has been previously suggested as the cause of previous live-RSV vaccine failures. This technology, appropriately developed and integrated into an RSV vaccination agenda, may be useful in improving the efficacy of current or future RSV vaccines.

Potential Commercial Applications: Competitive Advantages:
  • Improvements to current RSV vaccines
  • Public health vaccination programs
  • Enhancing antibody response and T-cell costimulation for targeted immunogenic outcomes
  • Pharma development programs focusing on care for neonates, children and the elderly
 
  • Increased expression of Th1-type cytokines and antibody production
  • Enhanced CD40 costimulation
  • May overcome prior live-RSV vaccine issues (which generated a primarily Th2-type immune response) by steering post-vaccination immunity further towards a preferred Th1-type (IL-2 and IFN-gamma) response, enhancing virus clearance in vivo


Development Stage:
  • In vitro data available
  • In vivo data available (animal)


Inventors:

Ralph Tripp (CDC)  ➽ more inventions...

Larry Anderson (CDC)  ➽ more inventions...

Michael Brown (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,371,392 issued 2008-05-13
U.S. Pat: 8,354,115 issued 2013-01-15
US Application No. 10/182,093
US Application No. 12/098,236
Various international patents issued

Publications:
Tripp RA, et al. PMID 10820273

Licensing Contact:
Karen Surabian, J.D., M.B.A.
Email: karen.surabian@nih.gov
Phone: 301-594-9719

OTT Reference No: E-233-2013/0
Updated: Feb 6, 2014